Nicht aus der Schweiz? Besuchen Sie lehmanns.de
New Rapid-acting Antidepressants -

New Rapid-acting Antidepressants

Kenji Hashimoto, Mario Manto (Herausgeber)

Buch | Softcover
VII, 149 Seiten
2022 | 1st ed. 2021
Springer International Publishing (Verlag)
978-3-030-79792-8 (ISBN)
CHF 269,60 inkl. MwSt
  • Versand in 15-20 Tagen
  • Versandkostenfrei
  • Auch auf Rechnung
  • Artikel merken
​This book discusses new candidates for rapid-acting antidepressants, such as (R)-ketamine, (2R,6R)-hydroxynorketamine, scopolamine, mGluR2/3 antagonists and AMPA receptor agonists.
This book discusses new candidates for rapid-acting antidepressants, such as (R)-ketamine, (2R,6R)-hydroxynorketamine, scopolamine, mGluR2/3 antagonists and AMPA receptor agonists.  There are serious limitations to currently available antidepressants, such as delayed onset and low rates of efficacy.  The discovery that a single dose of ketamine, an NMDAR antagonist, can produce rapid antidepressant effects that are sustained has led to new research in this area.  In this volume, a variety of novel pharmaceutical treatments are examined.  This volume would be useful to both researchers and clinicians who work in the field of pharmacology, specifically CNS drug treatments.

First Name – Kenji Last Name – Hashimoto Institution - Chiba University Center for Forensic Mental Health Department - Division of Clinical Neuroscience City – Chiba 260-8670 State – Chiba Country – Japan Email – hashimoto@faculty.chiba-u.jp Kenji Hashimoto, PhD Chiba University, Chiba, Japan Dr. Hashimoto is a professor and vice-director of Chiba University Center for Forensic Mental Health from 2005. Dr. Hashimoto graduated from Faculty of Pharmaceutical Sciences at Kyushu University, and received PhD. After Dr. Hashimoto worked at Fukuyama University, National Institutes of Health (NIH)/National Institute of Drug Addiction (NIDA)(Baltimore, MD, USA) and Pharmaceutical company, he moved at Chiba University Graduate School of Medicine from 2001. Dr. Hashimoto works on the development of novel therapeutic drugs for psychiatric and neurological disorders. Dr. Hashimoto published more than 550 articles in PubMed listed publications. Dr. Hashimoto focus on the molecular and cellular mechanisms of ketamine’s antidepressant actions.

(R)-ketamine: A new rapid-acting antidepressant.- (2R,6R)-hydroxynorketamine, a metabolite of ketamine: the antidepressant actions and the mechanisms.- Predictable biomarkers for rapid-acting antidepressant response to ketamine.- Nitrous Oxide: an old compound with emerging psychotropic properties.- Novel AMPA receptor potentiators TAK-137 and TAK-653 as potential rapid-acting antidepressants.- AMPA receptor potentiators as potential rapid-acting antidepressants.- mGlu2/3 receptor antagonists as rapid-acting antidepressants.- Antidepressant effects of the muscarinic receptor antagonist scopolamine: Clinical and preclinical review.

Erscheinungsdatum
Reihe/Serie Contemporary Clinical Neuroscience
Zusatzinfo VII, 149 p. 14 illus., 9 illus. in color.
Verlagsort Cham
Sprache englisch
Maße 155 x 235 mm
Gewicht 253 g
Themenwelt Medizin / Pharmazie Medizinische Fachgebiete Psychiatrie / Psychotherapie
Medizin / Pharmazie Studium
Naturwissenschaften Biologie Humanbiologie
Naturwissenschaften Biologie Zoologie
Schlagworte GABA receptor • glutamate receptor • IL-6 antibody • mGluR receptor • Muscarinic receptor • NMDA Receptor
ISBN-10 3-030-79792-9 / 3030797929
ISBN-13 978-3-030-79792-8 / 9783030797928
Zustand Neuware
Haben Sie eine Frage zum Produkt?
Mehr entdecken
aus dem Bereich
Menschen mit psychischer Erkrankung wirksam unterstützen

von Matthias Hammer; Irmgard Plößl

Buch | Hardcover (2023)
Psychiatrie Verlag
CHF 48,95